Teva

Bethel Free Clinic, a nonprofit medical establishment, provides complimentary healthcare services to those without insurance. It offers services including primary care, acute care, laboratory testing, health education, help with prescriptions, referrals to specialists, and preventive measures such as vaccinations and STD testing.

Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. It specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology that enables the creation of purified, stabilized, and functional GPCRs, known as StaRs (Stabilised Receptors), which addresses key challenges in the drug development process. The company offers a range of services including GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, and antibody discovery. Heptares has established strategic partnerships with several organizations, including Pfizer Inc., Kymab Limited, PeptiDream Inc., and Jitsubo Co., Ltd., to enhance its research and development capabilities. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.

Anda, Inc. is a wholesale distributor of pharmaceutical products in the United States, supplying a wide range of items including generic, branded, and specialty pharmaceuticals, as well as controlled substances, vaccines, injectables, medical and surgical supplies, and over-the-counter products. The company caters to independent pharmacies, pharmacy chains, hospitals, nursing homes, mail order pharmacies, and physicians' offices, facilitating orders through phone, fax, and online platforms. Founded in 1992 and based in Weston, Florida, Anda, Inc. was previously known as Anda Generics, Inc. and adopted its current name in October 1999. It operates as a subsidiary of Watson Pharmaceuticals, Inc.

Wave Life Sciences Ltd. is a clinical-stage genetic medicine company focused on developing innovative RNA-based therapies. Utilizing its proprietary PRISM platform, the company designs, optimizes, and produces stereopure oligonucleotides aimed at addressing genetic defects. By targeting ribonucleic acid (RNA), Wave aims to either diminish the production of harmful proteins or convert dysfunctional proteins into functional ones. The company's primary focus is on neurology, particularly disorders affecting the central and neuromuscular systems. Wave Life Sciences has established research and collaboration agreements with major pharmaceutical companies, including Pfizer and Takeda, to further advance its therapeutic programs. Founded in 2012 and headquartered in Singapore, Wave Life Sciences is dedicated to delivering transformative treatments for patients with genetically defined diseases.

Rimsa, a leading pharmaceutical manufacturing and distribution company in Mexico

CareTRx by Gecko Health is a product and services to improve poor medication adherence for asthma and COPD medication. The company offers a unique solution based on direct monitoring, games and social tools that motivate patients, engage care-givers, and inform clinicians. GeckoCap simplifies adherence to help families and lower costs.

Actavis plc is a global specialty pharmaceutical company that focuses on developing, manufacturing, and distributing generic, brand, and biosimilar products. With global headquarters in Dublin, Ireland, and Administrative Headquarters in Parsippany, New Jersey, USA, Actavis is committed to providing a wide range of pharmaceutical products to meet the needs of patients worldwide.

MicroCHIPS Biotech, Inc. specializes in developing a microchip-based implant designed for drug delivery applications across various therapeutic areas, including osteoporosis, diabetes, multiple sclerosis, women’s contraception, and pain management. This innovative implant can store and release precise doses of medication over extended periods, offering an alternative to traditional therapies that rely on frequent injections. The implant is surgically placed under the skin during a minimally invasive procedure and can be wirelessly activated or deactivated by healthcare providers or patients. Additionally, the device allows for real-time adjustments to the drug dosage and frequency, catering to the specific needs of each patient. Established in 1999 and headquartered in Lexington, Massachusetts, MicroCHIPS operates as a subsidiary of Daré Bioscience, Inc.

Auspex Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for orphan diseases, particularly those involving involuntary movement disorders. The company’s pipeline features product candidates aimed at addressing significant unmet medical needs, including hyperkinetic movement disorders such as chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. Auspex Pharmaceuticals specializes in creating deuterated analogs of clinically-validated drugs, enhancing existing therapies across various therapeutic areas, including respiratory disease and inflammation. Through its focused approach, the company seeks to provide effective treatment options for patients suffering from these challenging conditions.

Ignyta, Inc. is a biotechnology company focused on discovering, developing, and commercializing molecularly targeted therapies aimed at treating cancer and autoimmune diseases. Established in 2011 and based in San Diego, California, Ignyta is dedicated to advancing personalized medicine by integrating therapeutic approaches with companion diagnostics. Its notable products include entrectinib, a tyrosine kinase inhibitor targeting various receptor proteins, and RXDX-105, which is designed for RET-driven solid tumors. The company seeks to improve treatment outcomes by identifying patients most likely to benefit from specific therapies through biomarker-based diagnostics. In 2018, Ignyta became a subsidiary of Roche Holdings, further enhancing its capabilities in precision medicine.

Labrys Biologics Inc. is a biotechnology company dedicated to developing treatments for chronic migraine. The company has secured worldwide rights to RN-307, an antibody initially developed by Pfizer Inc., specifically designed for the treatment of chronic migraine. Additionally, Labrys Biologics is advancing its lead candidate, LBR-101, which is an anti-CGRP monoclonal antibody aimed at preventing chronic and high-frequency migraines. Through these innovative therapies, Labrys Biologics aims to address the significant unmet medical needs of individuals suffering from chronic migraine conditions.

NuPathe Inc., a Pennsylvania-based specialty pharmaceutical company, specializes in developing and commercializing branded therapeutics for neurological and psychiatric disorders. Its primary product, Zecuity, is a transdermal patch used for acute migraine treatment. NuPathe's pipeline includes NP201, a long-acting treatment for Parkinson's disease, and NP202, a long-term therapy for schizophrenia and bipolar disorder, both leveraging the company's biodegradable implant technology. NuPathe, now a subsidiary of Teva Pharmaceuticals, focuses on innovative neuroscience solutions and actively seeks partnerships to maximize the global potential of its product candidates.

MicroDose Therapeutx is a specialty pharmaceutical company based in South Brunswick Township, New Jersey, focused on developing advanced drug delivery products. Its primary innovations include a novel electro-mechanical dry powder inhaler and PolyCap technologies, which aim to enhance the efficacy and convenience of pharmaceutical treatments. The company serves the pharmaceutical and biotechnology industries, providing innovative solutions that address the challenges of traditional drug delivery methods.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Cocrystal Discovery is a privately funded biotechnology company developing antiviral therapeutics for human diseases. Cocrystal has breakthrough technologies that enable the creation of first- and best-in-class antivirals. Their mission today is to discover and develop small molecule inhibitors of the viral replication complex.

Cephalon is a global biopharmaceutical company founded in 1987 and headquartered in Frazer, Pennsylvania. The company specializes in discovering, developing, and marketing medications aimed at improving the quality of life for patients worldwide. Cephalon focuses on therapeutic areas including central nervous system disorders, cancer, pain, and inflammatory diseases. It has successfully brought to market several first-in-class and best-in-class products, offering over 150 branded and generic medications in nearly 100 countries. With a workforce of approximately 4,000 employees, Cephalon has established itself as one of the fastest-growing companies in the biopharmaceutical sector. Its products are distributed both in the United States and internationally, reflecting its commitment to addressing a diverse range of health challenges.

Cima Labs is a pharmaceutical and biotechnology company that focuses on developing advanced drug delivery technologies. It specializes in orally disintegrating tablets (ODT), oral transmucosal (OTM) systems, and oral powder formulations. Cima Labs partners with other companies to utilize its innovative delivery methods, which are designed to enhance the effectiveness and commercialization of pharmaceutical products. Through its proven expertise in drug delivery solutions, Cima Labs plays a significant role in improving patient compliance and therapeutic outcomes.

Barr Pharmaceuticals was a global specialty pharmaceutical company that operated in more than 30 countries worldwide.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

TransPharma Medical Ltd. is a specialty pharmaceutical company dedicated to the development and commercialization of innovative drug products using advanced transdermal drug delivery technology. The company focuses on creating solutions that enable painless delivery of peptide and protein therapeutics. Its flagship product, ViaDerm-hPTH (1-34), is designed to treat osteoporosis and is currently undergoing Phase 2B clinical trials in collaboration with Eli Lilly. In addition to this, TransPharma Medical is advancing two other peptide products that are in Phase 1 of clinical development. Through its proprietary delivery systems, the company aims to improve patient outcomes in the treatment of various conditions.

BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company's development pipeline includes several therapeutic candidates, such as BL-8040, a peptide designed for treating solid tumors, hematological malignancies, and facilitating stem cell mobilization. Another key candidate is AGI-134, an immuno-oncology agent aimed at solid tumors. Additionally, BioLineRx has developed BL-5010, a proprietary pen-like applicator intended for the non-surgical removal of skin lesions. The company has established collaborations with prominent organizations, including MSD for cancer immunotherapy, MD Anderson Cancer Center to explore the combination of BL-8040 with KEYTRUDA in pancreatic cancer, and Genentech Inc. for studies involving BL-8040 and TECENTRIQ in solid tumors. Founded in 2003, BioLineRx is focused on addressing unmet medical needs and improving existing therapies in the pharmaceutical market.

Proneuron Biotechnologies focuses on developing innovative therapies aimed at treating spinal cord injuries and other central nervous system disorders. The company employs proprietary technology that modulates the interaction between the nervous and immune systems, which enhances cell therapy options for spinal cord-related injuries. In addition to spinal cord injury treatments, Proneuron is actively researching potential cures for paralysis and various neurological conditions, positioning itself as a key player in advancing therapeutic solutions in this critical area of healthcare.

Copley Pharmaceutical is a generic pharmaceutical company that manufactured products for both over-the-counter and prescription sales.